Posts Tagged: Kyle Bass
An entirely screwed up way of viewing the world of innovation
When a product or process worth stealing is created the party that is considered the innovator is the thief and the party that is considered to be …
PTAB ends Kyle Bass IPRs targeting Acorda patents on Ampyra MS treatment with no findings of obviousness
A panel of administrative patent judges (APJs) at the Patent Trial and Appeal Board (PTAB) issued a final written decision ending a series of inter partes review (…
What is Michelle Lee Hiding?
Michelle Lee talks about transparency, but the PTO is hiding behind redacted pages and claims of privilege to deny a legitimate FOIA request from Kyle Bass. “I …
The Year in Patents: The Top 10 Patent Stories from 2015
It is that time once again when we look back on the previous year in preparation to close the final chapter in order move fresh into the …
PTAB Hedge Fund Failures Diffuse Early Market Hysteria
The early “death squad” hysteria persisted just long enough to catch the interest of hedge funds. The hedge funds saw an opportunity to utilize the PTAB to …
Kyle Bass IPR challenge moves foward, what does it mean for patent reform?
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. Celgene Corporation filed a motion for sanctions against the …
Fat cats have the patent system perpetually on the brink
The stark reality of how government operates leaves us with a patent system that will be perpetually on the brink. Giant corporations have become effectively insulated from …
Inter Partes Review and the Controversial Implications of the Kyle Bass Petitions
I will moderate what should be a lively discussion on the PTAB and inter partes review. I will be joined by Erich Spangenberg, advisor to Kyle Bass …
With dubious logic and inaccurate statements of law, PTAB denies another Kyle Bass IPR petition
The PTAB said that the full pilot study had not been made of record, which apparently also meant to the Board that the available description of the …
USPTO denies Kyle Bass IPR patent challenge against Acorda Therapeutics
The USPTO declined to initiate an inter partes review of two patents owned by Acorda Therapeutics, Inc. Acorda patents were challenged by the Coalition for Affordable Drugs, …
PTAB to determine whether to sanction Kyle Bass for filing IPRs
According to Celgene, the Kyle Bass strategy of shorting a stock and filing an inter partes review challenge is an abuse of the process and not what …
It’s Time to Whack ‘IPR Trolls’
Having to defend their patent in post grant reviews such as an IPR can easily cost patent owners between $700,000 to over $1 million when the subject matter of …
Patent Reform 101 – A Primer on Pending Patent Legislation
Patent reform is the new normal and we can expect that it will continually be raised in every new Congress for the foreseeable future. Currently there are …
Mixed Reviews for the PATENT Act in the Senate
Microsoft applauded the introduction of the PATENT Act. Universities seem to be on the fence, recognizing that the Senate alternative is an improvement, but likely to support …
Patent Reform Advances on Capitol Hill
Yesterday the House Committee on Energy and Commerce voted to approve the Targeting Rogue and Opaque Letters (TROL) Act by a vote of 30-22. Meanwhile, the Protecting …
